249 related articles for article (PubMed ID: 17145833)
1. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
[TBL] [Abstract][Full Text] [Related]
2. Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.
Gabri MR; Ripoll GV; Alonso DF; Gómez DE
J Cancer Res Clin Oncol; 2002 Dec; 128(12):669-77. PubMed ID: 12474053
[TBL] [Abstract][Full Text] [Related]
3. Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.
Venier C; Guthmann MD; Fernández LE; Fainboim L
Clin Exp Immunol; 2007 Feb; 147(2):379-88. PubMed ID: 17223981
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.
Fernández A; Mesa C; Marigo I; Dolcetti L; Clavell M; Oliver L; Fernández LE; Bronte V
J Immunol; 2011 Jan; 186(1):264-74. PubMed ID: 21135171
[TBL] [Abstract][Full Text] [Related]
5. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.
Carr A; Mazorra Z; Alonso DF; Mesa C; Valiente O; Gomez DE; Perez R; Fernandez LE
Melanoma Res; 2001 Jun; 11(3):219-27. PubMed ID: 11468510
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP).
Estevez F; Carr A; Solorzano L; Valiente O; Mesa C; Barroso O; Sierra GV; Fernandez LE
Vaccine; 1999 Aug; 18(1-2):190-7. PubMed ID: 10501249
[TBL] [Abstract][Full Text] [Related]
7. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
8. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
Ma J; Wang YL; Hu HM; Fox BA; Si LS
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
[TBL] [Abstract][Full Text] [Related]
9. Subtherapeutic doses of interleukin-15 augment the antitumor effect of interleukin-12 in a B16F10 melanoma model in mice.
Lasek W; Golab J; Maśliński W; Switaj T; Bałkowiec EZ; Stokłosa T; Giermasz A; Malejczyk M; Jakóbisiak M
Eur Cytokine Netw; 1999 Sep; 10(3):345-56. PubMed ID: 10477391
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
11. Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer.
Aguilar FF; Barranco JJ; Fuentes EB; Aguilera LC; Sáez YL; Santana MD; Vázquez EP; Baker RB; Acosta OR; Pérez HG; Nieto GG
Vaccine; 2012 Oct; 30(46):6595-9. PubMed ID: 22921738
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors.
Torréns I; Mendoza O; Batte A; Reyes O; Fernández LE; Mesa C; Guillén G
Vaccine; 2005 Dec; 23(50):5768-74. PubMed ID: 16112257
[TBL] [Abstract][Full Text] [Related]
15. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma.
Kircheis R; Küpcü Z; Wallner G; Wagner E
Cytokines Cell Mol Ther; 1998 Jun; 4(2):95-103. PubMed ID: 9681248
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice.
Kircheis R; Küpcü Z; Wallner G; Rössler V; Schweighoffer T; Wagner E
Cancer Gene Ther; 2000 Jun; 7(6):870-8. PubMed ID: 10880017
[TBL] [Abstract][Full Text] [Related]
17. Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice.
Wysocki PJ; Kwiatkowska EP; Kazimierczak U; Suchorska W; Kowalczyk DW; Mackiewicz A
Clin Cancer Res; 2006 Jul; 12(13):4095-102. PubMed ID: 16818710
[TBL] [Abstract][Full Text] [Related]
18. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
[TBL] [Abstract][Full Text] [Related]
20. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity.
Guthmann MD; Bitton RJ; Carnero AJ; Gabri MR; Cinat G; Koliren L; Lewi D; Fernandez LE; Alonso DF; Gómez DE; Fainboim L
J Immunother; 2004; 27(6):442-51. PubMed ID: 15534488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]